Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

22.33 +0.48 (+2.20%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Acadia (ACAD) Q3 2025 Earnings Call Transcript
Acadia (ACAD) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
Earnings Scheduled For November 5, 2025
 
Via Benzinga
ACADIA Pharmaceuticals's Earnings: A Preview
 
Via Benzinga
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Presents a Compelling Growth and Breakout Profile
ACADIA Pharmaceuticals (ACAD) shows strong growth fundamentals and a positive technical setup, making it a stock to watch for a potential breakout. 
Via Chartmill
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire
This ACADIA Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Fits the 'Affordable Growth' Investment Framework
ACADIA Pharmaceuticals offers strong growth and profitability at a reasonable industry valuation, making it a prime candidate for affordable growth investors. 
Via Chartmill
Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth and Positive Technical Setup
ACADIA Pharmaceuticals shows strong EPS and revenue growth with a positive technical setup, making it a compelling growth stock candidate. 
Via Chartmill
Leap Therapeutics (LPTX) Plummets Over 20% Amidst Profit-Taking and Volatility Ahead of Key Clinical Data
Boston, MA – October 3, 2025 – Leap Therapeutics, Inc. (NASDAQ: LPTX) experienced a sharp downturn in its stock performance today, with shares falling by over 20% in intraday trading. This significant... 
Via MarketMinute
Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
From Acadia Pharmaceuticals Inc.
Via Business Wire
Beyond The Numbers: 11 Analysts Discuss ACADIA Pharmaceuticals Stock
In the preceding three months, 11 analysts have released ratings for ACADIA Pharmaceuticals (NASDAQ: ACAD), presenting a wide array of perspectives from bullish to bearish. 
Via Benzinga
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Presents an Affordable Growth Opportunity
Discover ACADIA PHARMACEUTICALS (ACAD), a strong affordable growth stock with impressive earnings, solid financials, and a reasonable valuation in the biotech sector. 
Via Chartmill
Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short
Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales in 2025 and highlights a strong pipeline outlook. 
Via Benzinga
Acadia Pharma Tumbles On Failed Appetite Suppressant; Soleno Surges
The companies are working on treatments for a rare, genetic disease that can cause excessive hunger. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study
The company noted that the safety and tolerability of intranasal Carbetocin were consistent with those observed in previous clinical trials. 
Via Stocktwits
Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint
From Acadia Pharmaceuticals Inc.
Via Business Wire
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Technical Setup for Potential Breakout
ACADIA Pharmaceuticals (ACAD) shows strong technical momentum with a high-quality consolidation pattern, signaling a potential breakout opportunity for traders. 
Via Chartmill
Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology
From Acadia Pharmaceuticals Inc.
Via Business Wire
Assessing ACADIA Pharmaceuticals: Insights From 12 Financial Analysts
 
Via Benzinga
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Emerges as a Top Affordable Growth Stock
ACADIA Pharmaceuticals (ACAD) offers strong growth metrics and a reasonable valuation within the biotech sector, making it a top affordable growth stock pick. 
Via Chartmill
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer
From Acadia Pharmaceuticals Inc.
Via Business Wire
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A Strong Affordable Growth Stock with Fair Valuation and High Potential
ACADIA Pharmaceuticals (ACAD) offers strong growth, fair valuation, and solid financial health, making it a top pick for the Affordable Growth investment strategy. 
Via Chartmill
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Combines Strong Fundamentals with Bullish Technicals for Growth Potential
ACADIA Pharmaceuticals (ACAD) shows strong growth fundamentals with rising revenue, EPS, and solid margins, plus a bullish technical breakout, making it a promising stock pick. 
Via Chartmill
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.